pBItetDMPKSGFP Citations (3)

Originally described in: RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
Lee JE, Bennett CF, Cooper TA Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4221-6. doi: 10.1073/pnas.1117019109. Epub 2012 Feb 27. PubMed Journal

---

Articles Citing pBItetDMPKSGFP

Articles
Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. Repellin M, Carton F, Boschi F, Galie M, Perduca M, Calderan L, Jacquier A, Carras J, Schaeffer L, Briancon S, Lollo G, Malatesta M. Nanomedicine. 2023 Jan;47:102623. doi: 10.1016/j.nano.2022.102623. Epub 2022 Oct 26. PubMed
CRISPR Diagnostics for Quantification and Rapid Diagnosis of Myotonic Dystrophy Type 1 Repeat Expansion Disorders. Asano K, Yoshimi K, Takeshita K, Mitsuhashi S, Kochi Y, Hirano R, Tingyu Z, Ishida S, Mashimo T. ACS Synth Biol. 2024 Dec 20;13(12):3926-3935. doi: 10.1021/acssynbio.4c00265. Epub 2024 Nov 20. PubMed
DM1 repeat-expanded RNAs confer RNA toxicity as individual nuclear-retained RNAs. Ouyang JPT, Shukla S, Bensalah M, Parker R. Cell Rep. 2025 May 27;44(5):115582. doi: 10.1016/j.celrep.2025.115582. Epub 2025 Apr 14. PubMed

If you have published an article using this material, please email us at to have your article added to this page.